Aardvark Therapeutics, Inc.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$57.6M
- Total assets
- $117.2M
- Market cap
- $80.3M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $62.7M
- Operating income
- -$62.7M
- Income tax
- $0
- Net income
- -$57.6M
- EPS (basic)
- $-2.93
- EPS (diluted)
- $-2.93
Balance sheet
- Total assets
- $117.2M
- Current assets
- $111.9M
- Total liabilities
- $10.5M
- Current liabilities
- $10.5M
- Shareholders’ equity
- $106.6M
Cash flow
- Operating cash flow
- -$54.2M
- Investing cash flow
- -$49.7M
- Financing cash flow
- $89.2M
- Net cash flow
- -$14.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $80.3M
- EPS (diluted)
- $-2.93
- Shares outstanding
- 22.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 13, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $57.6M.
- Trading 79% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aardvark Therapeutics, Inc..
Write a review
News about Aardvark Therapeutics, Inc.
News & sentiment via Polygon.io
